The mechanisms underlying sperm protein 17 (Sp17) gene expression in myeloma cells remained unclear. Using reverse transcription -polymerase chain reaction (RT -PCR), Sp17 transcripts were detected in ARK-B, ARP-1, RPMI-8226 and KMS-11 but not in H929, IM-9, MM1-R and U266 cells. Using a panel of primer pairs in methylation-sensitive PCR to amplify overlapping gene segments, our screening studies showed that the HpaII sites at À359 and À350 are involved in the regulation of Sp17 gene expression. To confirm the differences in methylation status between Sp17-positive and Sp17-negative cell lines, KMS-11 cells (Sp17-positive) and IM-9 cells (Sp17-negative) were subjected to the more accurate method of bisulphite conversion. KMS-11 cells were more hypomethylated at these HpaII sites of exon 1 compared to IM-9 cells, indicating the association of hypomethylated promoter with Sp17 gene expression. In addition, the level of methylation at other CpG sites within the promoter sequence was also higher in IM-9 than KMS-11. Exon 1 was cloned into a reporter vector, pCAT*3 Enhancer. Chloramphenicol acetyl transferase ( Even though Sp17 shows a restricted normal tissue expression, the mechanisms regulating Sp17 aberrant expression in myeloma cells are not known. We therefore set out to determine the mechanisms of the Sp17 gene expression since such information may provide the opportunity to manipulate the gene for therapeutic purposes. Changes in gene methylation occur frequently in cells that have undergone malignant transformation. These changes are thought to be responsible for the aberrant expression of the genes encoding some CT antigens. Since Sp17 is a CT antigen, we hypothesised that Sp17 gene expression might be controlled by methylation of the promoter sequence so that the gene is silenced by DNA methylation. To test this hypothesis, we have investigated Sp17 gene expression in eight MM cell lines and
Sp17 is involved in the interaction of spermatozoa with oocytes after acrosome reaction (in mouse) (Kong et al, 1995) and after sperm -zona pellucida contact is initiated (in rabbit) (Richardson et al, 1994) . In addition, it has a functional role in cell regulation by participating in signalling pathways through its calmodulin binding site at the C-terminal (Wen et al, 2001) . The N-terminal is similar to a cAMP-dependent protein kinase regulatory subunit and the central domain participates in heparin binding ( Recently, an intronless Sp17 pseudogene (Sp17-2) has been identified in human in chromosome 10 and is attributed to RNA retroposition.
COS cells transfected with Sp17 cDNA showed Sp17 in their cytoplasm (Yamasaki et al, 1995) . Although Sp17 does not have a transmembrane domain, Sp17 was also found on the surface of live COS cells. The explanation for this observation is not apparent. It is possible that Sp17 has an unknown mechanism for arriving at the cell surface by lipid associations or carrier proteins. Alternatively, it could have arisen due to cell death and subsequent release of cytoplasmic Sp17 that became associated with the membrane.
Even though Sp17 shows a restricted normal tissue expression, the mechanisms regulating Sp17 aberrant expression in myeloma cells are not known. We therefore set out to determine the mechanisms of the Sp17 gene expression since such information may provide the opportunity to manipulate the gene for therapeutic purposes. Changes in gene methylation occur frequently in cells that have undergone malignant transformation. These changes are thought to be responsible for the aberrant expression of the genes encoding some CT antigens. Since Sp17 is a CT antigen, we hypothesised that Sp17 gene expression might be controlled by methylation of the promoter sequence so that the gene is silenced by DNA methylation. To test this hypothesis, we have investigated Sp17 gene expression in eight MM cell lines and Reverse transcription -polymerase chain reaction performed. Briefly, all RNA specimens were first treated with DNAse I (Ambion Inc., Austin, TX, USA) to remove genomic DNA contamination. First-strand cDNA was synthesised from 1 mg of total RNA using a random hexamer primer. The PCR primers were 5 0 SP17PCR: 5 0 -CAG CAG AAT GGG GGA GTA AG-3 0 ; and 3 0 SP17PCR: 5 0 -CAG CTT GGA TTT TGA CAG CA-3 0 . Polymerase chain reaction was performed using 35 amplification cycles at an annealing temperature of 601C. Negative controls in all the PCR reactions contained the PCR reaction mixture except for cDNA, which was substituted with water. RNA integrity in each sample was checked by amplification of a b-actin gene segment. Successful removal of genomic DNA contamination was confirmed in each sample by amplification of the RNA without prior RT reaction. Polymerase chain reaction products were visualised on an ethidium bromide agarose gel. All results were confirmed on two independent RT -PCRs.
Methylation-sensitive PCR
A panel of oligonucleotide primers was used to amplify overlapping gene segments on the Sp17 exon 1 or a control gene segment in exon 5 of Sp17 gene (Table 1) . Genomic DNA was extracted from tumour cells using a commercially available DNA extraction kit. The DNA was digested for 3 h at 371C with 10 U mg À1 methylation-sensitive restriction enzyme HpaII, extracted with phenol and chloroform -isoamyl alcohol (25 : 24 : 1), and recovered by ethanol precipitation. To ensure completion of digestion, the above process was repeated. This restriction digest protocol has been used successfully in previous works (De Smet et al, 1996; Sigalotti et al, 2002) and has been found to result consistently in complete digestion of the genomic DNA by HpaII restriction enzyme. Following ethanol precipitation, 100 ng of the digested DNA was used for amplification in a final volume of 50 ml PCR mixture. Polymerase chain reaction was carried out for 30 cycles in a thermal cycler. Polymerase chain reaction products were analysed on a 2% agarose gel and visualised by ethidium bromide staining. All results were confirmed in two independent PCR.
Sodium bisulphite genomic DNA modification
Genomic DNA was first digested with EcoRI, then denatured with 0.3 M NaOH for 15 min. The denatured DNA was then reacted with 3.6 M sodium bisulphite and 1 mM hydroquinone (551C for 14 h). The DNA was desalted using a DNA clean-up kit (Wizard DNA Clean Up, Promega, Madison, WI) and precipitated for PCR. Polymerase chain reaction was carried out using the oligonucleotide primers that amplify the whole exon 1 of Sp17 gene: 5 0 -ACC TAA CTA GCT TCG CCT CCT TC-3 0 ; and 5 0 -CTC CTT TCT CTC CGA GCT GGT GC-3 0 . The PCR products were cloned into the TAcloning system. Eight recombinant clones were randomly picked from each transfection for nucleotide sequence analysis to determine the proportion of hypomethylated promoter sequence.
In vitro methylation of plasmids, cell transfection and analysis of chloramphenicol acetyl transferase (CAT) expression Sp17 promoter sequence contained within exon 1 was isolated, amplified and cloned into TA-cloning system for sequence analysis. The sequence was identical to that published recently . We then subcloned the promoter DNA into the pCAT*3 Enhancer vector between KpnI and BglII.
The plasmid was methylated in each CpG dinucleotide with SssI methylase according to the manufacturer's instruction. Control Sp17 promoter methylationunmethylated plasmid was obtained under similar experimental conditions but without the addition of the SssI methylase. Methylated (pCAT*3 Enhancer-Sp17promoter/met) or unmethylated (pCAT*3 Enhancer-Sp17 promoter) plasmids were purified by phenol and chloroform extractions, followed by ethanol precipitation. Successful methylation of the plasmid was confirmed by restriction digest using methylation-sensitive HpaII. Once generated, both pCAT*3 Enhancer-Sp17promoter/met and pCAT*3 Enhancer-Sp17promoter were used to transfect the human embryonic kidney cell line, 293 cells. Transfection was carried out using the FuGENE 6 reagent (Roche Molecular Biochemicals) according to the manufacturer's recommendation. Briefly, the cells were seeded into a six-well cluster plate and grown to 50% confluence. The cultures were transfected with 2 mg of the plasmids and assayed for CAT activities after 72 h. FAST CAT Green (deoxyl) Chloramphenicol Acetyltransferase Assay Kit (Molecular Probes, Eugene, OR, USA) was used to detect CAT activity. The transfectants were lysed and a cytoplasmic extract prepared. The extract was then incubated with the fluorescent deoxylchloramphenicol substrate and acetyl CoA at 371C. The reaction was terminated by the addition of ice-cold ethyl acetate. After drying and dissolution in ethyl acetate, the reaction substrate and product were resolved by thin-layer chromatography on silica gel plates and eluted with a chloroform:methanol mixture (85 : 15 (v v À1 )).
In vitro treatment of myeloma cell lines with 5-azacytidine
Tumour cells were treated with 2 mM 5-azacytidine. The medium was replaced daily with fresh culture medium and after 96 h, the cells were used for molecular analyses. Control cultures were grown under identical conditions but without 5-azacytidine.
Northern blot analysis
Total RNA was prepared from the cells using a commercially available RNA preparation kit, RNAEasy (Qiagen, USA). Total RNA (10 mg) from each cell preparation were electrophoresed on a 1.2% agarose/formaldehyde gel and transferred onto a nylon membrane (MSI, Westboro, MA, USA 
Statistical analysis
Fisher's exact tests were used to determine the significance of differences between two variables. A P-value of p0.05 was considered statistically significant. 
RESULTS

Confirmation of association between Sp17 gene expression and hypomethylation by bisulphite sequencing
Restriction digest/PCR analysis is sensitive to undigested DNA that will cause amplification of the unmethylated alleles. Therefore, to confirm the results obtained from restriction digest/PCR indicating differences in the methylation status of these HpaII sites between Sp17-positive and Sp17-negative myeloma cells, genomic DNA from one Sp17-positive, KMS-11, and one Sp17-negative, IM-9, cells were selected for further analysis by bisulphite conversion. Following this, the genomic DNA underwent PCR and cloning. Eight randomly picked recombinant clones were subjected to nucleotide sequence analysis. We first examined the sequences at the eight HpaII sites covered by the six primer pairs to validate the PCR primers we have used. A combination of methylated and demethylated sequences was obtained, indicating that the primers we have used were able to amplify both methylated and demethylated exon 1. Therefore, any results obtained were unlikely to be due to preferentially amplification of methylated sequences. We next examine the sequences to validate the results we have obtained in KMS-11 and IM-9 from restriction digest/PCR. A complete correlation was observed between the results from sequence analysis and those from restriction digest/PCR (Table 2) . Only HpaII sites within the gene segments from KMS-11 cells amplified by primer pairs II and IV showed complete demethylation, validating the results of the restriction digest/PCR that showed no PCR product after HpaII digest. In contrast, the other HpaII sites from KMS-11 or IM-9 all showed variable or complete methylation, as predicted by the restriction digest/PCR experiments. These results therefore support the notion that methylation at the two HpaII sites covered by primer pair IV may be involved in the regulation of Sp17 gene expression. A total of 46 CpG sites were identified within the Sp17 exon 1. In addition to differences at the HpaII sites, the 46 CpG sites were more hypomethylated in Sp17-positive KMS-11 cells (82%, range 80 -98%) than Sp17-negative IM-9 cells (27%, range 4 -50%) (Po0.001), indicating the association of Sp17 gene expression with global promoter hypomethylation (Figure 3) .
Suppression of CAT reporter gene transcription by in vitro methylation of Sp17 promoter
Exon 1 of Sp17 gene is about 666 bp and is rich in CpG dinucleotides. It fits the criteria for being a CpG island that is often associated with a promoter region. To prove that exon 1 contains the Sp17 promoter sequence, we used the constructed pCAT*3 Enhancer-Sp17promoter in a transient transfection study on 293 human embryonic kidney cells. In contrast to cells transfected with the wild-type plasmid, CAT activity was obtained from lysate of cells transfected with pCAT*3 Enhancer-Sp17pro-moter, confirming that exon 1 contains Sp17 promoter sequence (Figure 4) .
To prove that methylation of the Sp17 promoter was sufficient to prevent expression, we constructed the reporter plasmids pCAT*3 Enhancer-Sp17promoter/met containing the Sp17 promoters individual cell lines. To prove that the upregulation of Sp17 gene expression was related to promoter hypomethylation, bisulphite conversion was carried out using genomic DNA from IM-9 cells, before and after preincubation in 5-azacytidine. Significantly more clones showed hypomethylation at the two HpaII sites amplified by primer pair IV (at position À350, increased from 0 to 62.5% and at position À359; increased from 12.5 to 50%; Po0.001) after exposure to 5-azacytidine, further supporting the possible involvement of the sequence around these two sites in the control of Sp17 gene expression. Compared to IM-9 cells that did not express Sp17 gene when cultured in control medium, the promoter sequence of IM-9 cells preincubated with 5-azacytidine also showed more global hypomethylation at the CpG islands (69 vs 27%, Po0.0005). (Scanlan et al,  2002) . However, the levels were less than 3% of the level detected in normal testis and the biological meaning of such low-level expression is unclear. In the light of the results from the present study, the apparent conflicting data are not surprising because random DNA methylation/demethylation errors can occur and are responsible for leaking expression of the Sp17 genes in some normal tissues.
DISCUSSION
In conclusion, we have elucidated the mechanisms responsible for the regulation of Sp17 gene expression in MM tumour cell lines. Although DNA methylation is not the primary control mechanism regulating the expression of most tissue-specific genes, our results indicate that promoter methylation can serve as the main regulatory mechanism for the expression of Sp17 in tumour cell lines. The susceptibility to induction of Sp17 in tumour cells by hypomethylating agent further supports the role of DNA methylation in silencing Sp17 gene. Our findings may have therapeutic implications and provides possible explanation to the leaky expression of Sp17 in some normal tissues observed in some studies.
